Rogerio Vivaldi is Executive Vice President and Chief Global Therapeutics Operations Officer. Prior to joining Bioverativ, Rogerio was Chief Commercial Officer at Spark Therapeutics, a gene therapy company focused on rare diseases, where he was responsible for building the global structure to commercialize future gene therapy products, the Medical Affairs organization, and the Patient Advocacy group. Prior to that, Rogerio co-founded and was President and CEO of Minerva Neurosciences, a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from neuropsychiatric diseases.  Before joining Minerva, Rogerio led the rare disease business at Genzyme, where he earned a reputation as a passionate advocate for patients. His experience there included serving as president of the Rare Diseases business and the Renal & Endocrine group, and as senior vice president and general manager of the company's Latin America group.  Rogerio began his career as a physician and spent 18 years in private practice in the clinical specialty areas of diabetes and endocrinology. He received his medical degree from Universidade do Rio de Janeiro (UNIRIO) Medical School, and completed his residency in endocrinology at Universidade do Estado do Rio de Janeiro (UERJ) and his fellowship at Mount Sinai Hospital Center in New York in the department of genetics, with an emphasis on Gaucher disease. He received his MBA degree from COPPEAD, Universidade Federal do Rio de Janeiro (UFRJ). Rogerio Vivaldi is Executive Vice President and Chief Global Therapeutics Operations Officer. Prior to joining Bioverativ, Rogerio was Chief Commercial Officer at Spark Therapeutics, a gene therapy company focused on rare diseases, where he was responsible for building the global structure to commercialize future gene therapy products, the Medical Affairs organization, and the Patient Advocacy group. Prior to that, Rogerio co-founded and was President and CEO of Minerva Neurosciences, a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from neuropsychiatric diseases.  Before joining Minerva, Rogerio led the rare disease business at Genzyme, where he earned a reputation as a passionate advocate for patients. His experience there included serving as president of the Rare Diseases business and the Renal & Endocrine group, and as senior vice president and general manager of the company's Latin America group.  Rogerio began his career as a physician and spent 18 years in private practice in the clinical specialty areas of diabetes and endocrinology. He received his medical degree from Universidade do Rio de Janeiro (UNIRIO) Medical School, and completed his residency in endocrinology at Universidade do Estado do Rio de Janeiro (UERJ) and his fellowship at Mount Sinai Hospital Center in New York in the department of genetics, with an emphasis on Gaucher disease. He received his MBA degree from COPPEAD, Universidade Federal do Rio de Janeiro (UFRJ).

Management